Anemia of Acute Inflammation Clinical Trial
Official title:
Anemia of Inflammation: Investigation on Impaired Iron Regulation in Acutely Ill Patients and Their Clinical Outcome
Anemia of inflammation (AI), a normochromic, normocytic anemia, associated with abnormal
iron utilization, erythropoietin hyporesponsiveness, and decreased red blood cells (RBC)
survival is a very common problem in hospitalized patients for acute inflammatory diseases
and develops within few days from the onset of illness. Deleterious effects of anemia
include increased risk of cardiac related morbidity and mortality in critically ill and
older patients.
Anemia is mediated by hepcidin, the 25-amino acid polypeptide hormone that is central to
iron trafficking.
Several studies have been performed on pathophysiology of AI in patients affected by chronic
diseases but few explore iron metabolism in humans with acute inflammation.
The aim is to develop effective new strategies to detect and manage AI in the setting of
acutely ill patients, based on the understanding of iron balance underlying this disorder.
n/a
Observational Model: Cohort, Time Perspective: Prospective